SEPN Key Statistics, Chart & Performance
The current stock price of SEPN is 25.635 USD. In the past month the price decreased by -9.5%. In the past year, price increased by 44.32%.
SEPN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SEPN. When comparing the yearly performance of all stocks, SEPN is one of the better performing stocks in the market, outperforming 88.99% of all stocks.
SEPN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SEPN. No worries on liquidiy or solvency for SEPN as it has an excellent financial health rating, but there are worries on the profitability.
SEPN Financial Highlights
Over the last trailing twelve months SEPN reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -53868.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.88% | ||
| ROE | -14% | ||
| Debt/Equity | 0 |
SEPN Forecast & Estimates
14 analysts have analysed SEPN and the average price target is 33.81 USD. This implies a price increase of 31.87% is expected in the next year compared to the current price of 25.635.
For the next year, analysts expect an EPS growth of 85.32% and a revenue growth 5487.18% for SEPN
SEPN Ownership
About SEPN
Company Profile
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 75 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Company Info
SEPTERNA INC
250 East Grand Avenue, Suite 65
South San Francisco CALIFORNIA US
Employees: 75
Phone: 16503383533
SEPTERNA INC / SEPN FAQ
What does SEPN do?
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 75 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Can you provide the latest stock price for SEPTERNA INC?
The current stock price of SEPN is 25.635 USD. The price decreased by -3.88% in the last trading session.
What is the dividend status of SEPTERNA INC?
SEPN does not pay a dividend.
What is the ChartMill rating of SEPTERNA INC stock?
SEPN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about SEPTERNA INC (SEPN) stock?
14 analysts have analysed SEPN and the average price target is 33.81 USD. This implies a price increase of 31.87% is expected in the next year compared to the current price of 25.635.
What is the employee count for SEPN stock?
SEPTERNA INC (SEPN) currently has 75 employees.
What is the outstanding short interest for SEPTERNA INC?
The outstanding short interest for SEPTERNA INC (SEPN) is 3.33% of its float.